Neuromedin U (NmU) -a neuropeptide belonging to the neuromedin family- plays a substantial role in HER2-positive breast cancer, correlating with increased aggressiveness, resistance to HER2-targeted therapies and overall significantly poorer outcome for patients. However, the mechanism through which it exerts these effects remains unclear. To elucidate this, initially we used HER2-positive breast cancer cells stably over-expressing NmU. These cells and their released extracellular vesicles (EVs) had increased amounts of the immunosuppressive cytokine TGFβ
Ireland ->
Trinity College Dublin ->
Pharmacy and Pharmaceutical Sciences (Scholarly Publications)
Ireland ->
Trinity College Dublin ->
Pharmacy and Pharmaceutical Sciences
Ireland ->
Trinity College Dublin ->
RSS Feeds
Ireland ->
Trinity College Dublin ->
PubMed
Ireland ->
Trinity College Dublin ->
School of Pharmacy and Pharmaceutical Sciences
Ireland ->
Trinity College Dublin ->
RSS Feeds
Lorraine O'Driscoll,
John Crown,
Aled Clayton,
Susan Breslin,
Josephine Salimu,
Sadhbh O'Neill,
Vanesa G Martinez
